Stemline Therapeutics, Inc.

AstraZeneca’s Phase III SERENA-6 study of camizestrant could usher in a new treatment paradigm by using biomarker testing to detect emerging resistance in breast cancer and change therapy without wait

The sheer number of US FDA’s novel drug approvals in 2023 contrasts with the generally moderate, steady performance of the Center for Drug Evaluation and Research over the year, including a median rev

While Menarini Group / Stemline Therapeutics, Inc. ’s leading oral selective estrogen receptor degrader (SERD) Orserdu has got off to a strong start following its February launch for breast cancer, n

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Takeda, F-star Sign Joint Research Pact